Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in ... Read More
Novartis acquires optogenetics gene therapy company Vedere Bio
Novartis acquisition of Vedere Bio : US-based stealth-stage company Vedere Bio has been acquired by Swiss pharma giant Novartis in a deal worth up to ... Read More
Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round
California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 ... Read More
BioMarin, DiNAQOR to develop gene therapies for rare genetic cardiomyopathies
BioMarin Pharmaceutical has signed a preclinical collaboration and license deal with Swiss gene therapy platform company DiNAQOR to develop novel gene therapies for the treatment ... Read More
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in ... Read More
Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
Cellectis said that it has dosed the first patient in a phase 1 study - the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf ... Read More
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene ... Read More
Roche to strengthen gene therapy portfolio with Spark Therapeutics acquisition
Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 ... Read More
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics to expand gene therapy portfolio
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a biotech firm specializing in the development of ... Read More